PT  - JOURNAL ARTICLE
AU  - Vinall, Maria
ED  - Andtbacka, Robert H. I.
TI  - OPTiM Study Results
DP  - 2013 Aug 01
TA  - MD Conference Express
PG  - 17--17
VI  - 13
IP  - 6
4099  - http://mdc.sagepub.com/content/13/6/17.1.short
4100  - http://mdc.sagepub.com/content/13/6/17.1.full
AB  - Results from the Efficacy and Safety Study of OncoVEX Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Compared to GM-CSF in Melanoma [OPTiM; NCT00769704; Andtbacka RHI et al. J Clin Oncol 2013 (suppl; abstr LBA9008)] showed that a genetically modified version of herpes simplex virus type 1 (talimogene laherparepvec), is safe and improves durable response rate in patients with unresectable stage IIIB-IV melanoma.